CD33 and acute myeloid leukemia: CD33-specific aptamers have properties comparable to anti-CD33 antibodies in terms of binding and internalization into CD33-positive myeloid cell lines, and they also have the potential to carry chemotherapeutic drugs to CD33-positive cells in adult and pediatric patients with AML [43].